

Maximum residue level for recombinant equine chorionic gonadotropin (reCG)

Published by AGRINFO on 31 Aug 2026

EU decides no MRL is required for recombinant equine chorionic gonadotropin (reCG)

Commission Implementing Regulation (EU) [2026/1806](#) of 24 July 2026 amending Regulation (EU) No 37/2010 as regards the classification of the substance recombinant equine chorionic gonadotropin with respect to its maximum residue limit in foodstuffs of animal origin

Update

The European Union (EU) has decided that recombinant equine chorionic gonadotropin (reCG), a biological substance primarily used in veterinary medicines for treating horses, does not require a maximum residue level (MRL). This applies to its use in all food-producing species.

Impacted products

Foods of animal origin

What is changing?

The EU has decided that reCG, an active substance primarily used in veterinary medicines for the treatment of horses, does not require an MRL. It is therefore classified as “No MRL required” in the list of pharmacologically active substances (Regulation [37/2010](#), Annex, Table 1). This classification applies to all food-producing species.

Why?

The European Medicines Agency (EMA) evaluates biological substances under the EU’s residue control framework. Following a 2025 application for evaluation from Syn Vet-Pharma Ireland Limited, the EMA’s Committee for Veterinary Medicinal Products (CVMP) concluded that no further MRL assessment was necessary because reCG is similar to naturally occurring substances and is expected to follow the same degradation process in the human digestive tract ([CVMP 2026](#)).

Timeline

The Regulation applies from **13 August 2026**.

Background

A list of pharmacologically active substances that can be used in veterinary medicines for food-producing animals is set out in Regulation [37/2010](#). This list includes a classification regarding MRLs. Substances are assessed according to the risk principles set out in Regulation [2018/782](#).

Resources

CVMP (2026) [Recombinant equine Chorionic Gonadotropin \(reCG\): Summary of assessment](#), 16 April.

Commission Regulation (EU) [2018/782](#) establishing the methodological principles for the risk assessment and risk management recommendations referred to in Regulation (EC) No 470/2009

Commission Regulation (EU) No [37/2010](#) on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin

Sources

Commission Implementing Regulation (EU) [2026/1806](#) as regards the classification of the substance recombinant equine chorionic gonadotropin with respect to its maximum residue limit in foodstuffs of animal origin

Visit the [AGRINFO website](#) to view the latest AGRINFO Update newsletters and [search](#) the database.

Disclaimer: *Under no circumstances shall COLEAD be liable for any loss, damage, liability or expense incurred or suffered that is claimed to have resulted from the use of information available on this website or any link to external sites. The use of the website is at the user's sole risk and responsibility. This information platform was created and maintained with the financial support of the European Union. Its contents do not, however, reflect the views of the European Union.*